This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Topical Antibiotics and Intravitreous Injections

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Christopher Ta, Stanford University
ClinicalTrials.gov Identifier:
NCT00410891
First received: October 2, 2006
Last updated: May 13, 2014
Last verified: May 2014
  Purpose
Evaluation of efficacy of topical preoperative antibiotics in patients undergoing intravitreous injections.

Condition Intervention Phase
Intravitreous Injections Drug: gatifloxacin Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Investigator)

Resource links provided by NLM:


Further study details as provided by Christopher Ta, Stanford University:

Primary Outcome Measures:
  • Conjunctival Bacterial Flora [ Time Frame: 3 days ]
    number of bacteria on the conjunctiva

  • Positive Culture [ Time Frame: 2 ]

Enrollment: 129
Study Start Date: July 2008
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: topical antibiotic
topical gatifloxacin 4 times per day
Drug: gatifloxacin

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • intravitreous injection

Exclusion Criteria:

  • antibiotic use
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00410891

Locations
United States, California
Stanford
Stanford, California, United States, 94304
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Christopher Ta, MD Stanford University
  More Information

Responsible Party: Christopher Ta, Principle Investigator, Stanford University
ClinicalTrials.gov Identifier: NCT00410891     History of Changes
Other Study ID Numbers: 96803 (eProtocol 4384
Study First Received: October 2, 2006
Results First Received: May 13, 2014
Last Updated: May 13, 2014

Additional relevant MeSH terms:
Anti-Bacterial Agents
Gatifloxacin
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents

ClinicalTrials.gov processed this record on August 21, 2017